药物开发
药物发现
时间轴
交叉口(航空)
计算机科学
计算生物学
数据科学
药品
风险分析(工程)
翻译科学
化学
生化工程
纳米技术
药理学
医学
梅德林
管理科学
制药工业
小分子
开发(拓扑)
转化医学
工程伦理学
过程开发
监管科学
化学空间
转化研究
作者
Kaicheng U,Sophia Meixuan Zhang,Ziyu Yu,Zechuan Zhang,Jianwei Zhang,Chang He,Anbang Liu,Rui Chen,Stella Wang,Lijie Yan,Shichao Ding,Lavonda Li,Zongxin Yang,Gao Xiao,Xushuai Zhang,Kaige Bao,Haohan Wang,Athanasios V. Vasilakos,Junhan Zhao,Siwei Chen
摘要
predictions and experimentally validated drug candidates. While a small but growing number of AI-guided molecules have entered clinical development, systematic evidence on whether AI-driven approaches ultimately deliver better drugs or faster timelines than traditional methods is still accruing. We discuss emerging opportunities at the intersection of AI with automation, robotics, multimodal biology, protein structure prediction, and autonomous discovery. With rigorous validation, high-quality datasets, and appropriate regulatory frameworks, AI can become a dependable tool for discovering safer, more effective, and more personalized medicines.
科研通智能强力驱动
Strongly Powered by AbleSci AI